JP2014521958A - 胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法 - Google Patents

胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法 Download PDF

Info

Publication number
JP2014521958A
JP2014521958A JP2014523039A JP2014523039A JP2014521958A JP 2014521958 A JP2014521958 A JP 2014521958A JP 2014523039 A JP2014523039 A JP 2014523039A JP 2014523039 A JP2014523039 A JP 2014523039A JP 2014521958 A JP2014521958 A JP 2014521958A
Authority
JP
Japan
Prior art keywords
fluid
cells
cancer
ligand
intrathoracic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014523039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521958A5 (https=
Inventor
アルベルダ，ステイーブン・エム
シユエド，ダニエル
ラオ，ガラ・チヤンドラ
コネリー，マーク
フアウルク，ブラド
Original Assignee
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
ベリデツクス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア, ベリデツクス・エルエルシー filed Critical ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Publication of JP2014521958A publication Critical patent/JP2014521958A/ja
Publication of JP2014521958A5 publication Critical patent/JP2014521958A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
JP2014523039A 2011-07-28 2012-07-27 胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法 Pending JP2014521958A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512576P 2011-07-28 2011-07-28
US61/512,576 2011-07-28
PCT/US2012/048452 WO2013016600A2 (en) 2011-07-28 2012-07-27 Methods and reagents for diagnosing conditions and characterization of tumor cells associated with serous fluids

Publications (2)

Publication Number Publication Date
JP2014521958A true JP2014521958A (ja) 2014-08-28
JP2014521958A5 JP2014521958A5 (https=) 2015-09-03

Family

ID=46650901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523039A Pending JP2014521958A (ja) 2011-07-28 2012-07-27 胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法

Country Status (6)

Country Link
US (1) US20140295426A1 (https=)
EP (1) EP2737317A2 (https=)
JP (1) JP2014521958A (https=)
IL (1) IL230687A0 (https=)
TW (1) TW201312117A (https=)
WO (1) WO2013016600A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6238856B2 (ja) * 2014-08-25 2017-11-29 シスメックス株式会社 尿中異型細胞の分析方法、尿分析装置および体液中異型細胞の分析方法
CA3000438C (en) * 2015-09-28 2024-05-14 The Governing Council Of The University Of Toronto Device for magnetic profiling of particles in a flow
US10696961B2 (en) 2017-12-01 2020-06-30 Global Life Sciences Solutions Usa Llc Magnetic cell isolation techniques
CA3082861A1 (en) * 2017-12-01 2019-06-06 General Electric Company Methods for cell enrichment and isolation
EP4073511A4 (en) 2019-12-12 2024-01-17 University of Miami MATERIALS AND METHODS FOR DETECTING EXTRACELLULAR VESICLES
CN115997008A (zh) 2020-04-22 2023-04-21 艾欧凡斯生物治疗公司 协调用于患者特异性免疫疗法的细胞的制造的系统和方法
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4259164A1 (en) 2020-12-11 2023-10-18 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
JP2024501845A (ja) 2020-12-31 2024-01-16 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス
EP4301138A2 (en) 2021-03-05 2024-01-10 Iovance Biotherapeutics, Inc. Tumor storage and cell culture compositions
US20240191191A1 (en) 2021-03-19 2024-06-13 Iovance Biotherapeutics, Inc. Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
JP2024512029A (ja) 2021-03-25 2024-03-18 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
CA3215830A1 (en) 2021-04-19 2022-10-27 Rafael CUBAS Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
JP2024527961A (ja) 2021-07-28 2024-07-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
WO2023039488A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
US20250000903A1 (en) 2021-09-24 2025-01-02 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
CA3243416A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
US20260021181A1 (en) 2022-08-01 2026-01-22 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4612277A1 (en) 2022-11-04 2025-09-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
JP2025539816A (ja) 2022-11-21 2025-12-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法
WO2025015318A2 (en) 2023-07-13 2025-01-16 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor
WO2026050217A2 (en) 2024-08-27 2026-03-05 Iovance Biotherapeutics, Inc. Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63109793A (ja) * 1986-10-28 1988-05-14 Kyowa Hakko Kogyo Co Ltd 抗ヒト中皮細胞単クロ−ン性抗体
JPH09510779A (ja) * 1994-03-10 1997-10-28 フォドスタッド オイステイン 特定化あるいは混合した細胞母集団または混合細胞母集団を含む溶液内の特定標的細胞を検出する方法および装置
JP2008538509A (ja) * 2005-04-21 2008-10-30 カリフォルニア インスティチュート オブ テクノロジー パリレンメンブレンフィルターの使用
JP2009525478A (ja) * 2006-01-31 2009-07-09 ビオメリュー 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用
JP2010501549A (ja) * 2006-08-23 2010-01-21 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー 胆管癌治療用薬学的組成物、胆管癌の成長または浸潤抑制方法、および胆管癌の治療方法
WO2010102177A1 (en) * 2009-03-06 2010-09-10 Becton, Dickinson And Company Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939240A (en) 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
AU656716B2 (en) 1989-09-15 1995-02-16 Genetic Systems Corporation Hybridoma CT43 producing a monoclonal antibody to a mucin epitope of colorectal cancer
CA2144750A1 (en) 1992-09-17 1994-03-31 Rolf Stahel Tumor-specific antibodies and antigen
US6660159B1 (en) 1996-06-07 2003-12-09 Immunivest Corporation Magnetic separation apparatus and methods
US6890426B2 (en) 1996-06-07 2005-05-10 Immunivest Corporation Magnetic separation apparatus and methods
US6790366B2 (en) 1996-06-07 2004-09-14 Immunivest Corporation Magnetic separation apparatus and methods
JP3996644B2 (ja) 1996-06-07 2007-10-24 イムニベスト・コーポレイション 外部及び内部勾配を有する磁気分離
US6136182A (en) 1996-06-07 2000-10-24 Immunivest Corporation Magnetic devices and sample chambers for examination and manipulation of cells
BR9907852A (pt) 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
US7282350B2 (en) 1998-02-12 2007-10-16 Immunivest Corporation Labeled cell sets for use as functional controls in rare cell detection assays
US6623982B1 (en) 1999-07-12 2003-09-23 Immunivest Corporation Increased separation efficiency via controlled aggregation of magnetic nanoparticles
CA2434604C (en) 2001-02-12 2010-09-28 Immunivest Corporation Cartridge for containing a specimen sample for optical analysis
WO2003019141A2 (en) * 2001-08-23 2003-03-06 Immunivest Corporation Analysis of circulating tumor cells, fragments, and debris
GB2395270B (en) * 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
JP4912894B2 (ja) * 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
US20060024824A1 (en) * 2004-07-16 2006-02-02 Steven Woodside Magnetic cell separation method
US7846743B2 (en) * 2005-04-21 2010-12-07 California Institute Of Technology Uses of parylene membrane filters
EP2037265A1 (en) * 2007-09-17 2009-03-18 Adnagen AG Solid phase cell isolation and/or enrichment method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63109793A (ja) * 1986-10-28 1988-05-14 Kyowa Hakko Kogyo Co Ltd 抗ヒト中皮細胞単クロ−ン性抗体
JPH09510779A (ja) * 1994-03-10 1997-10-28 フォドスタッド オイステイン 特定化あるいは混合した細胞母集団または混合細胞母集団を含む溶液内の特定標的細胞を検出する方法および装置
JP2008538509A (ja) * 2005-04-21 2008-10-30 カリフォルニア インスティチュート オブ テクノロジー パリレンメンブレンフィルターの使用
JP2009525478A (ja) * 2006-01-31 2009-07-09 ビオメリュー 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用
JP2010501549A (ja) * 2006-08-23 2010-01-21 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー 胆管癌治療用薬学的組成物、胆管癌の成長または浸潤抑制方法、および胆管癌の治療方法
WO2010102177A1 (en) * 2009-03-06 2010-09-10 Becton, Dickinson And Company Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERIC KIELHORN: "USE OF MAGNETIC ENRICHMENT FOR DETECTION OF CARCINOMA CELLS IN FLUID SPECIMENS", CANCER, vol. V94 N1, JPN5015000886, 1 January 2002 (2002-01-01), pages 205 - 211, ISSN: 0003313015 *
MASAHIRO HORIKAWA, ONCOLOGY REPORTS, vol. V25 N5, JPN5015000877, 18 February 2011 (2011-02-18), pages 1413 - 1420, ISSN: 0003313016 *

Also Published As

Publication number Publication date
WO2013016600A3 (en) 2013-04-18
EP2737317A2 (en) 2014-06-04
US20140295426A1 (en) 2014-10-02
TW201312117A (zh) 2013-03-16
IL230687A0 (en) 2014-03-31
WO2013016600A2 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
JP2014521958A (ja) 胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法
JP5479355B2 (ja) 血液中の循環黒色腫細胞の自動計数及び特徴付け
JP4593557B2 (ja) 循環腫瘍細胞（ｃｔｃ）：転移癌患者における増悪までの時間、生存および療法に対する応答の早期評価
US20140113310A9 (en) Cancer detection markers
US20070154960A1 (en) Method for assessing disease states by profile analysis of isolated circulating endothelial cells
WO2010065968A1 (en) Cancer detection markers
JP2008533487A (ja) 循環腫瘍細胞を用いる転移性乳癌患者の療法中の各追跡期間ポイントでの無増悪および全生存を予測する方法
US20080113350A1 (en) Blood test to monitor the genetic changes of progressive cancer using immunomagnetic enrichment and fluorescence in situ hybridization (FISH)
JP2024023284A (ja) がんのスクリーニング、診断、治療、及び再発における巨細胞の核酸の特徴付けの使用方法
Quirós‐Caso et al. Routine flow cytometry approach for the evaluation of solid tumor neoplasms and immune cells in minimally invasive samples
KR20190045200A (ko) 방광암용 바이오마커로서의 케라틴 17
WO2005116264A2 (en) A blood test to monitor the genetic changes of progressive cancer using immunomagnetic enrichment and fluorescence in situ hybridization (fish)
Tkaczuk et al. The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method
JP6707505B2 (ja) 腫瘍細胞を検出するためのステロイド受容体アッセイ
JP2012022002A (ja) 循環腫瘍細胞を用いる転移性乳癌患者の療法中の各追跡期間ポイントでの無増悪および全生存を予測する方法
Slack et al. Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: correlation with immunocytochemistry and Western blot analysis
WO2022030626A1 (ja) 膀胱癌診断方法
WO2006020936A2 (en) A method for assessing disease states by profile analysis of isolated circulating endothelial cells
Xie et al. Detection of circulating rare cells benefitted the diagnosis of malignant solitary pulmonary nodules
BR102020026395A2 (pt) Método, painel e kit para o diagnóstico e monitoramento do tratamento de pacientes com câncer de mama
HK1190457A (en) Steroid receptor assays for detecting tumor cells
HK1195121B (en) Steroid receptor assays for detecting tumor cells
HK1195121A (en) Steroid receptor assays for detecting tumor cells
HK1148348B (en) Automated enumeration and characterization of circulating melanoma cells in blood

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170118